Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 2
1995 1
1996 1
1998 2
1999 3
2000 4
2001 5
2002 8
2003 6
2004 4
2005 4
2006 2
2007 4
2008 5
2009 4
2010 5
2011 9
2012 5
2013 7
2014 4
2015 1
2016 4
2017 6
2018 3
2019 5
2020 2
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 16585503

101 results

Results by year

Filters applied: . Clear all
Page 1
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R. Bielekova B, et al. Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5941-6. doi: 10.1073/pnas.0601335103. Epub 2006 Apr 3. Proc Natl Acad Sci U S A. 2006. PMID: 16585503 Free PMC article. Clinical Trial.
Daclizumab Therapy for Multiple Sclerosis.
Bielekova B. Bielekova B. Cold Spring Harb Perspect Med. 2019 May 1;9(5):a034470. doi: 10.1101/cshperspect.a034470. Cold Spring Harb Perspect Med. 2019. PMID: 29661806 Free PMC article. Review.
Daclizumab therapy for multiple sclerosis.
Bielekova B. Bielekova B. Neurotherapeutics. 2013 Jan;10(1):55-67. doi: 10.1007/s13311-012-0147-4. Neurotherapeutics. 2013. PMID: 23055048 Free PMC article. Review.
101 results